NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

Published on January 30, 2014 at 8:08 AM · No Comments

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.

The 22 categories of tumors covered in this series of tests are: brain, lung, breast, cervix, colorectal, endometrium, esophagus, stomach, ovary, soft tissue, thyroid, GIST (gastro intestinal stromal tumors), melanoma, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), AML favorable-risk, chronic lymphocytic leukemia (CLL), lymphoma, juvenile myelomonocytic leukemia (JMML), myeloproliferative neoplasms (MPN), cancer not-otherwise specified, and spliceosomal abnormalities. The genetic abnormalities are investigated using the most reliable technology including sequencing, Fluorescent In-Situ Hybridization (FISH), methylation analysis, fragment length analysis and SNP-cytogenetic array technology. 

Although more than 60 different genes are investigated in all these tumors, only 8 - 18 genes are investigated per patient or tumor type. For each type of cancer, we selected the key driver genes that are central to confirming diagnosis, predicting prognosis, determining or monitoring therapy, and exploring clinical trials options. In many cases, these driver genes can also be targeted for therapy.    

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment